Is GNW a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Genworth Financial (GNW) rests on Enact cash flow and the holding company discount: Enact is a well-capitalised mortgage insurer with a seasoned insurance-in-force book, and its dividends and buyback participation are Genworth's primary source of cash. The bear case rests on the core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

GNW key stats

At $8.31 on November 16, 2026, Genworth Financial (GNW) has a market cap of $3.0B and a P/E of 83.1 on trailing earnings (7.6 on forward earnings).

Market cap
$3.0B
P/E (trailing)
83.1
P/E (forward)
7.6
EPS (trailing 12 months)
$0.10
Price to book
0.4
Beta
0.86

Market cap, P/E and yield are measured at the $8.31 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Genworth Financial (GNW)?

The last two weeks for Genworth Financial, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • GNW closed at $8.31 on November 16, 2026, down 4.7% over the past five trading days (from $8.72).
  • On November 9, 2026, Genworth Financial filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
  • On November 5, 2026, Genworth Financial filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 4, 2026, Genworth Financial filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Genworth Financial, based in Richmond, Virginia, is what is left of a much larger insurer after two decades of restructuring. It reports three main pieces. Enact is a private mortgage insurance business that Genworth took public in 2021 and still owns roughly 81% of, and it produces essentially all of the group's operating earnings. The Long-Term Care Insurance segment is a closed block: policies written largely between the 1970s and the 2000s, no longer sold, whose claims and reserves Genworth manages down over decades. A smaller Life and Annuities segment is also in runoff. The newer effort is CareScout, which builds a quality-assured network of home care and senior living providers, earns fees on placements and preferred pricing, and through CareScout Insurance is writing fresh long-term care coverage on modern assumptions. Trailing twelve-month revenue is ~$7.4 billion against a market capitalisation of ~$3.41 billion at ~$9.02 per share as of October 16, 2026. The investment picture is dominated by one arithmetic gap. In August 2026 Enact carried a market value of ~$6.9 billion, so Genworth's ~81% was worth ~$5.5 billion, roughly 1.6x Genworth's market cap as of mid-October. The market is therefore assigning a negative value to everything else: the long-term care block, holding company debt, corporate expense, and CareScout's spending. Cash keeps moving up from Enact regardless, and Genworth expects ~$445 million to ~$485 million from it in 2026 out of ~$550 million to ~$600 million of total Enact capital returns, which funds share repurchases and debt reduction at the holding company. Q2 2026 adjusted operating income excluding the closed block was ~$112 million, or ~$0.29 per diluted share, while the closed block continued to record losses. Whether the discount narrows depends on the long-term care block behaving, and on whether repurchases at these prices are enough to force the issue. The shares have drifted lower since the summer. As of October 16, 2026 GNW closed near $9.02, roughly flat for the year (up about 0.5%) and up about 6% over one year, but down about 11% over three months, and Keefe, Bruyette & Woods downgraded the stock on October 9. Other recent developments were incremental: in September AM Best revised the outlooks on Genworth's rated entities to stable while affirming their ratings, Genworth said a UK court ruling limits its liability tied to Santander payment protection insurance claims, and it introduced a family caregiver benefit that lets eligible long-term care policyholders use coverage for care from family members. Genworth holds its Q3 2026 earnings call on November 5, with analysts expecting adjusted EPS of about $0.27.

The bull case for GNW

1. Enact cash flow and the holding company discount.

Enact is a well-capitalised mortgage insurer with a seasoned insurance-in-force book, and its dividends and buyback participation are Genworth's primary source of cash. Management guided to ~$445 million to ~$485 million of Enact capital reaching Genworth in 2026. As long as that stream continues, the discount between Genworth's market cap and the market value of its Enact stake is the single largest variable in the story.

2. The multi-year rate action plan on legacy long-term care.

Genworth has been raising premiums and offering benefit reductions on the closed block since 2012, an effort it calls the multi-year rate action plan, with an estimated net present value of ~$34.8 billion of approved actions as of June 30, 2026. The plan has moved into a later stage where policyholders increasingly choose reduced benefits rather than higher premiums, which lowers future claims instead of raising current cash. Each incremental approval is a state-by-state regulatory decision, so progress is lumpy and never guaranteed. In September 2026 Genworth added a family caregiver benefit, which gives eligible policyholders another way to use their coverage and is part of the same effort to manage the block.

3. Capital returns against a discounted asset.

Genworth repurchased ~$62 million of stock in Q2 2026 and raised its 2026 repurchase outlook to ~$225 million to ~$250 million, alongside a ~$10 million reduction in holding company debt. Repurchasing shares that trade below the value of the Enact stake alone is mechanically accretive to the remaining holders if the long-term care block does not consume the difference. Holding company cash and liquid assets were ~$215 million at June 30, 2026, which sets the practical ceiling on the pace.

4. CareScout as the second act.

CareScout Services is targeting ~$25 million of revenue in 2026 against planned spending of ~$50 million to ~$55 million, so it consumes cash today. Match volumes have been pacing below the annual target management set, and the response has been to widen the network and add senior living placement fees on top of the home care pricing model. CareScout Insurance writing new long-term care policies is the piece that would eventually give Genworth an operating business again rather than a runoff and a stake.

5. Q3 2026 results in early November.

Genworth's adjusted EPS has come in at or above consensus in the first two quarters of 2026 ($0.28 vs $0.20 in Q1 and $0.29 vs $0.27 in Q2), and analysts expect about $0.27 for Q3 with the conference call on November 5. Full-year 2026 consensus is about $1.10. The release will update Enact cash flows to the holding company, the pace of buybacks against the raised ~$225 million to ~$250 million outlook, and any change in long-term care reserve assumptions.

The bear case for GNW

The core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere. Rate increases are approved one state at a time, so the multi-year rate action plan can slow without warning. Because Enact supplies almost all earnings and cash, a US housing downturn would hit Genworth twice, through mortgage delinquencies and through the market value of the stake itself. There is no announced plan to divest or distribute Enact, so the holding company discount can persist for years regardless of what the parts are worth. Genworth also remains a defendant in policyholder class actions over long-term care rate increase disclosures, and while the long-running securities class action was dismissed on summary judgment in August 2026, litigation outcomes are outside the company's control.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding GNW already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on GNW

Too few analysts publish on GNW for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The GNW forecast page covers what coverage does exist.

How is GNW valued?

Market cap, P/E and dividend yield at today's price are in the GNW key stats above. The business figures below come from Genworth Financial's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$7.38 billion (up ~5% year over year in the latest quarter)
  • Net income (TTM): ~$202 million; ~$0.50 trailing EPS
  • Enact stake: ~81% of Enact Holdings (ACT), worth ~$5.5 billion at Enact's ~$6.9 billion market value in August 2026
  • Adjusted operating income ex-closed block (Q2 2026): ~$112 million, or ~$0.29 per diluted share vs ~$0.27 consensus
  • Holding company cash and liquid assets: ~$215 million at June 30, 2026
  • 2026 share repurchase outlook: ~$225 million to ~$250 million (~$62 million repurchased in Q2 2026)

As of October 2026: Figures are approximate and tied to the asOf date; check live numbers before acting. Standard earnings multiples do little work here, because GAAP results consolidate all of Enact while charging the full drag of the long-term care closed block; the stock trades near 0.39x book and about 8x forward earnings, but reported equity includes the minority interest in Enact and swings with accumulated other comprehensive income. Most analysis of GNW is sum-of-the-parts instead: the market value of the Enact stake, less holding company debt and corporate costs, less whatever haircut the long-term care block deserves, and the shares falling about 11% in three months has widened that gap.

How do you decide if GNW is a buy?

Whether GNW is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold GNW indirectly through an index or sector ETF before adding more.

What would change your mind on GNW

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Enact cash flow and the holding company discount stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the GNW stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about GNW against your real portfolio and see your actual exposure before deciding.

Your questions about Genworth Financial

Ask Walnut's AI anything about GNW and see how it fits what you own.

FAQ

Is GNW a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Enact cash flow and the holding company discount, with revenue (ttm) at ~$7.38 billion (up ~5% year over year in the latest quarter). The bear case rests on the core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell GNW?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.

What is the bull case for GNW?

+

Enact cash flow and the holding company discount. Enact is a well-capitalised mortgage insurer with a seasoned insurance-in-force book, and its dividends and buyback participation are Genworth's primary source of cash.

What is the bear case for GNW?

+

The core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere. Rate increases are approved one state at a time, so the multi-year rate action plan can slow without warning. Because Enact supplies almost all earnings and cash, a US housing downturn would hit Genworth twice, through mortgage delinquencies and through the market value of the stake itself. There is no announced plan to divest or distribute Enact, so the holding company discount can persist for years regardless of what the parts are worth. Genworth also remains a defendant in policyholder class actions over long-term care rate increase disclosures, and while the long-running securities class action was dismissed on summary judgment in August 2026, litigation outcomes are outside the company's control.

What does Genworth Financial do?

+

Holding company whose value sits in an approximately 81 percent stake in mortgage insurer Enact, offset by a legacy long-term-care runoff block.

What would have to change for GNW to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Enact cash flow and the holding company discount) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the core risk is that the long-term care closed block turns out to cost more than reserved: morbidity, mortality, policyholder lapse behaviour and long-run interest rates all feed the reserve, and a deterioration can require capital that the holding company would rather deploy elsewhere) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Genworth Financial actually do?

+

Genworth is a holding company with three parts. It owns ~81% of Enact Holdings, a listed private mortgage insurer that provides nearly all group operating earnings. It runs off a closed block of long-term care insurance sold decades ago and no longer offered on those terms, plus a smaller life and annuity block. And it is building CareScout, a network of vetted home care and senior living providers with an insurance arm writing new long-term care coverage.

Why does GNW trade for less than its Enact stake is worth?

+

At Enact's ~$6.9 billion market value in August 2026, Genworth's ~81% was worth roughly $5.5 billion, against a GNW market cap of ~$3.41 billion as of October 16, 2026. The gap is the market's price for the long-term care closed block, holding company debt and corporate costs, and the uncertainty that the stake will ever be converted into cash for holders. Discounts like this can narrow through repurchases or a structural move, or persist for years.

What is the long-term care closed block and why does it lose money?

+

It is a portfolio of long-term care policies written mostly between the 1970s and the 2000s, priced before insurers understood how long claimants would live and how few would lapse. Genworth stopped writing on those terms and now manages the block down over decades, collecting premiums and paying claims. It still records losses because original pricing was too low, which is exactly what the rate action plan exists to fix.

Walnut is informational, not investment advice, and gives no verdict on GNW. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks